Indinavir

This classification denotes a protease inhibitor and anti-hiv agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W6YA9PKKH. European Medicines Agency schedules Indinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08174MIG. Indinavir generally arises in the molecular formula C36H47N5O4. The term INDINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, no. 3, 1996, list 36.) INDINAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Indinavir under HS 29335995 and SITC 51576. As of Q4 2014, INDINAVIR remains the US FDA Preferred Term for this commodity. Indinavir bears US NLM identifiers UMLS ID C0376637 and NCI Concept Code C66877. SMILES: CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2CCCCC2)C(=O)N[C@H]3C4CCCCC4C[C@H]3O)O)CC5CCCNC5.O.